European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 7 September 2026 - 16:32

Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 7 September 2026 - 16:20

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Arava, leflunomide, Date of authorisation: 02/09/1999, Revision: 46, Status: Authorised

Submitted by Anonymous (not verified) on 7 September 2026 - 16:00

Human medicines European public assessment report (EPAR): Arava, leflunomide, Date of authorisation: 02/09/1999, Revision: 46, Status: Authorised

Human medicines European public assessment report (EPAR): Nordimet, methotrexate, Date of authorisation: 18/08/2016, Revision: 26, Status: Authorised

Submitted by Anonymous (not verified) on 7 September 2026 - 15:26

Human medicines European public assessment report (EPAR): Nordimet, methotrexate, Date of authorisation: 18/08/2016, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Date of authorisation: 29/03/2017, Revision: 16, Status: Authorised

Submitted by Anonymous (not verified) on 7 September 2026 - 15:06

Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Date of authorisation: 29/03/2017, Revision: 16, Status: Authorised

EMA Methodology Working Party interested parties meeting 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 November 2026, 13:00 (CET) to 4 November 2026, 16:00 (CET)

Submitted by Anonymous (not verified) on 7 September 2026 - 10:35

EMA Methodology Working Party interested parties meeting 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 November 2026, 13:00 (CET) to 4 November 2026, 16:00 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness